Evidence map›Paper›PMID 39953210›Full record

SynthesisSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025

Efficacy of cannabinoids for the prophylaxis of chemotherapy-induced nausea and vomiting-a systematic review and meta-analysis.

Ronald Chow, Anna Basu, Jagdeep Kaur, David Hui, James Im, Elizabeth Prsic, Gabriel Boldt, Michael Lock, Lawson Eng, Terry L Ng and 2 more

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ronald ChowPrincess Margaret Cancer Centre, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada. ronald.chow@uhn.ca.
Anna BasuVerspeeten Family Cancer Centre, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada.
Jagdeep KaurVerspeeten Family Cancer Centre, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada.
David HuiThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
James ImFaculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
Elizabeth PrsicYale School of Medicine, Yale University, New Haven, CT, USA.
Gabriel BoldtVerspeeten Family Cancer Centre, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada.
Michael LockVerspeeten Family Cancer Centre, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada.
Lawson EngPrincess Margaret Cancer Centre, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Terry L NgFaculty of Medicine, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON, Canada.
Camilla ZimmermannPrincess Margaret Cancer Centre, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Florian ScotteGustave Roussy, Université Paris-Saclay Faculté de Médecine, Université Paris-Saclay, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCannabinoids have potential efficacy as prophylaxis for chemotherapy-induced nausea and vomiting (CINV), but no recent meta-analysis has reported on their relative efficacy compared to other antiemetics. The aim of this meta-analysis is to examine the relative efficacy of cannabinoids for prophylaxis of CINV.

methodsA literature search was conducted in OVID Medline, EMBASE, and Cochrane Central Register of Controlled Trials from inception up until March 2024. Articles were included if they reported on complete response, no nausea, no vomiting or no use of rescue medications, and were randomized controlled trials with cannabinoids in one arm. Meta-analysis was conducted for each endpoint and for a composite endpoint amalgamating existing endpoints. Subgroup analyses by medication used in control arm and by study design were conducted. Cumulative and leave-one-out analysis was also conducted. Type I error was set at 0.05.

resultsA total of 26 studies were included in this meta-analysis, of which 23 were published before the 2000s. Nearly half of the included studies had some concern for bias. Cannabinoid had superior overall CINV control compared to placebo (RR 2.65, 95% CI 1.70-4.12, I

conclusionsThere is scant evidence for efficacy of cannabinoids for CINV in the era of triple and quadruple antiemetics. Although THC:CBD showed promised in a recent trial, further trials should examine its safety and efficacy in the context of regimens containing olanzapine.

Indexed as

AntiemeticsAntineoplastic AgentsCannabinoidsNauseaVomitingHumansNeoplasmsRandomized Controlled Trials as TopicAntiemeticsAntineoplastic AgentsCannabinoidsAntiemeticCancerCannabinoidChemotherapy-induced nausea and vomiting

Identifiers

PMID39953210
PMCPMC11828838

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.